Psoriatic Arthritis
📧 Sign up to get email alerts when something new happens for Psoriatic Arthritis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-10-31FDA Approved: WEZLANA — Original Application (Nuvaila Limited)
This entry documents the original Biologics License Application for WEZLANA, a ustekinumab-AUUB monoclonal antibody developed by Nuvaila Lim…
-
FDA approval · 2023-10-20FDA Approved: ZYMFENTRA — Original Application (CELLTRION USA Inc.)
FDA approved ZYMFENTRA (inflximab-dyyb) from Celltrion USA as a biosimilar to infliximab (Remicade), based on demonstration of biosimilarity…
-
FDA approval · 2023-10-18FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)
The FDA approved a supplemental application for Enbrel (etanercept) submitted by Immunex Corporation.
-
CLINICAL_TRIALS trial_result · 2023-10-12Clinical Trial Update: Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis [Phase 3]
A Phase 3 clinical trial comparing BAT2506 with Simponi in participants with active psoriatic arthritis has completed.
-
FDA approval · 2023-10-06FDA Approved: COSENTYX — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Cosentyx (secukinumab) submitted by Novartis Pharmaceuticals Corporation.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-09-21FDA Approved: ADALIMUMAB — Supplemental Application (CELLTRION USA, Inc.)
FDA approved a supplemental Biologics License Application for the adalimumab biosimilar ADALIMUMAB-AATY from Celltrion USA, approving its bi…
-
CLINICAL_TRIALS trial_result · 2023-09-06Clinical Trial Update: PsA Secukinumab XCT Structural Progression Study [Phase 4]
Phase 4 trial update for secukinumab in psoriatic arthritis completed, reporting structural progression study results.
-
CLINICAL_TRIALS trial_result · 2023-08-25Clinical Trial Update: A Phase 3 Clinical Study of KHK 4827 [Phase 3]
Phase 3 trial update for KHK 4827 across psoriasis-related conditions; study completed.
-
CLINICAL_TRIALS trial_result · 2023-08-01Clinical Trial Update: Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis [Phase 2]
This Phase 2 trial update reports results from a study evaluating the effect of Filgotinib on semen parameters in adult males with active rh…
-
FDA approval · 2023-07-24FDA Approved: COSENTYX — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Cosentyx (secukinumab) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2023-07-19FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
The FDA approved a supplemental application for ADALIMUMAB-ADBM, a biosimilar of adalimumab from Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2023-06-30FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
The FDA approved a supplemental application for the adalimumab biosimilar ADALIMUMAB-ADBM from Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2023-06-14FDA Approved: ABRILADA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for ABRILADA (adalimumab-afzb) submitted by Pfizer Laboratories Div Pfizer Inc to update the labelin…
-
FDA approval · 2023-05-23FDA Approved: ADALIMUMAB — Original Application (CELLTRION USA, Inc.)
FDA approved ADALIMUMAB-AATY from CELLTRION USA, Inc. as a biosimilar to adalimumab under an Original Application for the same indications a…
-
FDA approval · 2023-05-18FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approved a supplemental application for ADALIMUMAB-ADBM, a biosimilar to adalimumab, from QUALLENT PHARMACEUTICALS HEALTH LLC.
-
FDA approval · 2023-04-14FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for adalimumab-adaz, a biosimilar to adalimumab, confirming its regulatory approval for use.
-
FDA approval · 2023-03-31FDA Approved: YUSIMRY — Supplemental Application (Coherus BioSciences Inc)
FDA approved a supplemental Biologics License Application for YUSIMRY (adalimumab-aqvh) by Coherus BioSciences, authorizing the biosimilar p…
-
CLINICAL_TRIALS withdrawal · 2023-03-15Clinical Trial Update: Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis [Phase 4]
A Phase 4 trial evaluating bimekizumab in psoriasis vulgaris with active psoriatic arthritis was withdrawn.
-
FDA approval · 2023-03-06FDA Approved: USTEKINUMAB — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for ustekinumab (Stelara) to expand its indications, as requested by Janssen Biotech, Inc.
-
CLINICAL_TRIALS trial_result · 2023-02-09Clinical Trial Update: To Evaluate the Efficacy and Safety of SHR0302 Tablet in Subjects of Active Psoriatic Arthritis [Phase 3]
Phase 3 clinical trial update evaluating SHR0302 tablet for efficacy and safety in active psoriatic arthritis.
-
CLINICAL_TRIALS trial_result · 2023-01-25Clinical Trial Update: National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
A national observational study assessing the real-world use of Inflectra (infliximab biosimilar) across multiple inflammatory diseases compl…
-
CLINICAL_TRIALS trial_result · 2023-01-20Clinical Trial Update: A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis [Phase 4]
Phase 4 clinical trial evaluating golimumab in Indian participants with active ankylosing spondylitis or psoriatic arthritis has completed. …
-
CLINICAL_TRIALS trial_result · 2022-12-19Clinical Trial Update: A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis [Phase 4]
Phase 4 clinical trial evaluating the effect of apremilast on MRI outcomes in adults with Psoriatic arthritis; results have been posted.
-
FDA approval · 2022-12-13FDA Approved: IDACIO — Original Application (Fresenius Kabi USA, LLC)
FDA approved IDACIO (adalimumab-afcf) from Fresenius Kabi USA, LLC as a biosimilar to adalimumab (Humira) under an original Biologics Licens…
-
FDA approval · 2022-11-29FDA Approved: JYLAMVO — Original Application (SHORLA ONCOLOGY INC.)
FDA approved JYLAMVO (methotrexate) under an Original Application from SHORLA ONCOLOGY INC.